Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$1.88B |
| 2 |
Pfizer
PFE
|
+$1.41B |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.17B |
| 4 |
Cisco
CSCO
|
+$1.1B |
| 5 |
Novartis
NVS
|
+$984M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$1.21B |
| 2 |
Adobe
ADBE
|
+$1.06B |
| 3 |
Stryker
SYK
|
+$955M |
| 4 |
Boston Scientific
BSX
|
+$695M |
| 5 |
Banco Santander
SAN
|
+$684M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.16% |
| 2 | Financials | 17.3% |
| 3 | Industrials | 10.45% |
| 4 | Healthcare | 9.91% |
| 5 | Energy | 8.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
MakeMyTrip
MMYT
$5.36B
| $617K | ﹤0.01% |
16,534
-29,791
| -64% | -$1.73M |
|
752
iShares US Technology ETF
IYW
$23.6B
| $615K | ﹤0.01% |
3,388
+833
| +33% | +$161K |
|
753
Jefferies Financial Group
JEF
$12.6B
| $611K | ﹤0.01% |
14,807
-2,100,509
| -99% | -$109M |
|
754
Clorox
CLX
$11.6B
| $608K | ﹤0.01% |
5,868
+233
| +4% | +$26.4K |
|
755
Generac Holdings
GNRC
$11.6B
| $606K | ﹤0.01% |
3,100
+867
| +39% | +$166K |
|
756
VanEck China Bond ETF
CBON
$26.3M
| $605K | ﹤0.01% |
25,951
| – | – |
|
757
Hackett Group
HCKT
$270M
| $598K | ﹤0.01% |
45,940
-42
| -0.1% | -$672 |
|
758
W.W. Grainger
GWW
$65.3B
| $595K | ﹤0.01% |
545
-21
| -4% | -$22.9K |
|
759
Cintas
CTAS
$81.9B
| $594K | ﹤0.01% |
3,512
-226
| -6% | -$43.3K |
|
760
JPMorgan Equity Premium Income ETF
JEPI
$45.9B
| $589K | ﹤0.01% |
10,397
+734
| +8% | +$42.7K |
|
761
iShares Core S&P Total US Stock Market ETF
ITOT
$94.3B
| $588K | ﹤0.01% |
4,124
+1,311
| +47% | +$195K |
|
762
Arthur J. Gallagher & Co
AJG
$64.1B
| $576K | ﹤0.01% |
2,659
+1,096
| +70% | +$253K |
|
763
Outdoor Holding Co
POWW
$249M
| $569K | ﹤0.01% |
283,333
-1,291,292
| -82% | -$2.46M |
|
764
Automatic Data Processing
ADP
$106B
| $566K | ﹤0.01% |
2,788
-3,353
| -55% | -$769K |
|
765
Aura Biosciences
AURA
$725M
| $559K | ﹤0.01% |
+83,508
| New | +$479K |
|
766
Invesco California AMT-Free Municipal Bond ETF
PWZ
$1.14B
| $552K | ﹤0.01% |
23,108
+1,108
| +5% | +$26.8K |
|
767
iShares Europe ETF
IEV
$1.67B
| $550K | ﹤0.01% |
8,090
-2,073
| -20% | -$146K |
|
768
TE Connectivity
TEL
$59.6B
| $550K | ﹤0.01% |
2,629
+224
| +9% | +$49.4K |
|
769
iShares MSCI EAFE Value ETF
EFV
$28.8B
| $547K | ﹤0.01% |
7,362
-2,735
| -27% | -$206K |
|
770
iShares Select Dividend ETF
DVY
$23.5B
| $546K | ﹤0.01% |
+3,607
| New | +$545K |
|
771
Semtech
SMTC
$11B
| $546K | ﹤0.01% |
7,100
+99
| +1% | +$8.14K |
|
772
American Century Quality Diversified International ETF
QINT
$665M
| $542K | ﹤0.01% |
+8,290
| New | +$555K |
|
773
Invesco S&P 500 Equal Weight ETF
RSP
$97B
| $542K | ﹤0.01% |
2,825
-1,151
| -29% | -$228K |
|
774
Williams Companies
WMB
$87.5B
| $542K | ﹤0.01% |
7,448
+1,771
| +31% | +$123K |
|
775
Elevance Health
ELV
$81.5B
| $541K | ﹤0.01% |
1,846
+556
| +43% | +$183K |
|
Similar funds
Ken Fisher's Q1 2026 Portfolio in Review
As of Q1 2026, Ken Fisher held 1,133 positions worth $295B, up 0.65% from $293B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Ken Fisher's Q1 2026 filing shows 116 new, 416 increased, 461 reduced and 117 closed positions. Its largest new stake was Portfolio Building Block World Pharma and Biotech Index ETF: 28,040,859 shares worth $717M. The largest sale was Abbott, an estimated $1.21B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Financials and Industrials.
- Ken Fisher's largest Q1 2026 buy was Portfolio Building Block World Pharma and Biotech Index ETF: 28,040,859 shares worth $717M.
- Ken Fisher added most to AbbVie in Q1 2026, an estimated $1.88B increase.
- Ken Fisher's biggest Q1 2026 reduction was Abbott, cutting an estimated $1.21B.
- Ken Fisher fully exited Trip.com Group in Q1 2026, selling an estimated $175M.
- Ken Fisher's ten largest holdings make up 33% of its $295B portfolio in Q1 2026.
- Ken Fisher opened 116 new positions and closed 117 in Q1 2026.
- Ken Fisher's portfolio value rose 0.65% quarter-over-quarter to $295B.
Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.